問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

蔡宛蓁
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

21Cases

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.
  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2026-04-01 - 2031-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting1Sites

2024-04-30 - 2027-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-08-01 - 2027-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-03-01 - 2027-11-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-10-01 - 2024-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2022-06-01 - 2023-09-06

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2024-10-31 - 2025-02-11

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-06-01 - 2027-10-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting7Sites

2024-10-10 - 2026-10-13

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3